Teva did not obtain marketing exclusivity. Mylan Inc. (NYSE: MYL) and India's Ranbaxy Laboratories Ltd. (BSE: 500359). Watson Pharmaceuticals Inc. (NYSE: WPI) also plans to market generic Actos, and are waiting for US Food and Drug Administration (FDA) approval. The company also asked for 180 days marketing exclusivity.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments